AU2020376801A1 - Methods and compositions for treatment of Rett syndrome - Google Patents
Methods and compositions for treatment of Rett syndrome Download PDFInfo
- Publication number
- AU2020376801A1 AU2020376801A1 AU2020376801A AU2020376801A AU2020376801A1 AU 2020376801 A1 AU2020376801 A1 AU 2020376801A1 AU 2020376801 A AU2020376801 A AU 2020376801A AU 2020376801 A AU2020376801 A AU 2020376801A AU 2020376801 A1 AU2020376801 A1 AU 2020376801A1
- Authority
- AU
- Australia
- Prior art keywords
- subject
- trofinetide
- administered
- rett syndrome
- daily amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Detergent Compositions (AREA)
- Chemical Or Physical Treatment Of Fibers (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962927008P | 2019-10-28 | 2019-10-28 | |
| US62/927,008 | 2019-10-28 | ||
| US202063031201P | 2020-05-28 | 2020-05-28 | |
| US63/031,201 | 2020-05-28 | ||
| PCT/US2020/057627 WO2021086892A1 (en) | 2019-10-28 | 2020-10-28 | Methods and compositions for treatment of rett syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2020376801A1 true AU2020376801A1 (en) | 2022-06-09 |
Family
ID=75715568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020376801A Pending AU2020376801A1 (en) | 2019-10-28 | 2020-10-28 | Methods and compositions for treatment of Rett syndrome |
Country Status (14)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023287750A1 (en) | 2021-07-12 | 2023-01-19 | Acadia Pharmaceuticals Inc. | Crystalline forms of trofinetide |
| WO2023242844A1 (en) * | 2022-06-15 | 2023-12-21 | Ramot At Tel-Aviv University Ltd. | Method and therapeutic agent for treatment of disease or disorder associated with impaired firing rate and/or mitochondrial calcium homeostasis |
| WO2025262646A1 (en) * | 2024-06-22 | 2025-12-26 | Biophore India Pharmaceuticals Pvt. Ltd | Dosage forms of trofinetide and its pharmaceutically acceptable salt thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6709817B1 (en) * | 1999-09-07 | 2004-03-23 | Baylor College Of Medicine | Method of screening Rett syndrome by detecting a mutation in MECP2 |
| LT2667715T (lt) * | 2011-01-27 | 2017-11-10 | Neuren Pharmaceuticals Limited | Autizmo spektro susirgimų gydymas, naudojant glicil-l-2-metilprolil-l-glutamo rūgštį |
| CN105358160A (zh) * | 2013-02-20 | 2016-02-24 | 瑟阿瓦斯克公司 | 亚硝酸盐的药物制剂及其用途 |
| SI3024463T1 (sl) * | 2013-07-25 | 2020-08-31 | Neuren Pharmaceuticals Limited | Nevroprotektivne biciklične spojine in postopki za njihovo uporabo pri zdravljenju motenj avtističnega spektra in nevrorazvojnih motenj |
| US20150224164A1 (en) * | 2013-11-26 | 2015-08-13 | Neuren Pharmaceuticals Limited | Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glumatic acid |
| GB2554064B (en) * | 2016-09-01 | 2019-11-20 | Jit Singh Shailinder | An enteral feeding tube |
-
2020
- 2020-10-28 KR KR1020227018117A patent/KR20220106982A/ko active Pending
- 2020-10-28 WO PCT/US2020/057627 patent/WO2021086892A1/en not_active Ceased
- 2020-10-28 JP JP2022552123A patent/JP2022553888A/ja active Pending
- 2020-10-28 AU AU2020376801A patent/AU2020376801A1/en active Pending
- 2020-10-28 CA CA3156680A patent/CA3156680A1/en active Pending
- 2020-10-28 CN CN202080090500.2A patent/CN115335071A/zh active Pending
- 2020-10-28 TW TW109137417A patent/TW202116300A/zh unknown
- 2020-10-28 MX MX2022004785A patent/MX2022004785A/es unknown
- 2020-10-28 EP EP20883589.2A patent/EP4051308A4/en active Pending
- 2020-10-28 IL IL292617A patent/IL292617B2/en unknown
- 2020-10-28 BR BR112022008095A patent/BR112022008095A2/pt unknown
-
2022
- 2022-02-01 US US17/590,496 patent/US20220339138A1/en active Pending
- 2022-04-28 CL CL2022001079A patent/CL2022001079A1/es unknown
- 2022-05-31 CO CONC2022/0007501A patent/CO2022007501A2/es unknown
-
2025
- 2025-07-10 JP JP2025116586A patent/JP2025148461A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025148461A (ja) | 2025-10-07 |
| IL292617B1 (en) | 2025-11-01 |
| WO2021086892A1 (en) | 2021-05-06 |
| BR112022008095A2 (pt) | 2022-07-12 |
| TW202116300A (zh) | 2021-05-01 |
| CA3156680A1 (en) | 2021-05-06 |
| US20220339138A1 (en) | 2022-10-27 |
| IL292617A (en) | 2022-07-01 |
| CO2022007501A2 (es) | 2022-08-30 |
| EP4051308A4 (en) | 2023-08-23 |
| EP4051308A1 (en) | 2022-09-07 |
| IL292617B2 (en) | 2026-03-01 |
| KR20220106982A (ko) | 2022-08-01 |
| JP2022553888A (ja) | 2022-12-26 |
| CL2022001079A1 (es) | 2023-04-21 |
| CN115335071A (zh) | 2022-11-11 |
| MX2022004785A (es) | 2022-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220339138A1 (en) | Methods and compositions for treatment of rett syndrome | |
| ES2726223T3 (es) | Composiciones que comprenden ketamina para el tratamiento de un trastorno del espectro autista | |
| JP2022529353A (ja) | 神経認知障害、慢性疼痛を治療し、炎症を低減させる方法 | |
| EP3909609A1 (en) | Methods for treatment of refractory generalized myasthenia gravis | |
| KR20250005175A (ko) | 양극성 장애의 치료를 위한 5-meo-dtm | |
| Araki et al. | Clinical practice guideline for chronic headache 2013 | |
| TW202341995A (zh) | 用於治療cns相關病症之神經活性類固醇 | |
| Toledo et al. | Long-term safety, efficacy, and quality of life during adjunctive brivaracetam treatment in patients with uncontrolled epilepsy: an open-label follow-up trial | |
| CN114126595A (zh) | 用于治疗抑郁症的艾司氯胺酮 | |
| Wartna et al. | Symptomatic treatment of pollen‐related allergic rhinoconjunctivitis in children: randomized controlled trial | |
| Evans et al. | Efficacy and safety of the melanocortin pan-agonist PL9643 in a phase 2 study of patients with dry eye disease | |
| Splinter | Efficacy of retigabine in adjunctive treatment of partial onset seizures in adults | |
| Egeberg et al. | Clinical overview of dalfampridine: an agent with a novel mechanism of action to help with gait disturbances | |
| Aurilio et al. | Opioids switching with transdermal systems in chronic cancer pain | |
| US10195165B2 (en) | Methods of treating Prader-Willi syndrome | |
| Nygaard et al. | The feasibility of perioperative methadone in older hip fracture patients: a pilot continual reassessment trial (MetaHip trial) | |
| EA051935B1 (ru) | Способы и композиции для лечения синдрома ретта | |
| Minden et al. | Treatment of disorders of mood and affect in multiple sclerosis | |
| Selvi et al. | Aripiprazole-related acute transient myopia and diplopia: a case report | |
| Babagi et al. | An overview on unipolar major depression in adults diagnosis and management approach | |
| US20230085440A1 (en) | Methods of preventing and treating pain and associated symptoms | |
| Sheikh et al. | Ab0288 safety of belimumab in patients with active systemic lupus erythematosus: year 2 follow-up of a large phase 4, randomised, double-blind, placebo-controlled study | |
| Data et al. | IHC Posters–Saturday and Sunday | |
| Tward | P191: Preliminary safety and efficacy of AK-OTOF gene therapy for otoferlin gene (OTOF)-mediated hearing loss | |
| Mao et al. | A novel dexmedetomidine nasal spray for gastrointestinal recovery in pediatric laparoscopic hernia repair: a randomized controlled trial |